Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Bladder Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
27 drugs · 88 active trials
2 drugs · 4 active trials
10 drugs · 164 active trials
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Gemcitabine | Approved | Phase 3 | 39 | 14 | 25 | 126 | 1 | US | Sep 9, 2025 | 1997-09 |
| Pembrolizumab | Approved | Phase 4 | 36 | 16 | 6 | 65 | 2 | US | Sep 4, 2014 | Jul 17, 2014 |
| Cisplatin | Approved | Phase 3 | 27 | 10 | 17 | 93 | 1 | US | Dec 19, 1978 | 1995-05 |
| Enfortumab Vedotin | Approved | Phase 4 | 20 | 14 | 4 | 24 | 2 | EU, US | Dec 18, 2019 | Jun 27, 2018 |
| Mitomycin | Approved | Phase 4 | 16 | 8 | 17 | 36 | 1 | US | Jun 12, 2025 | 1991-09 |
| Atezolizumab | Approved | Phase 3 | 12 | 2 | 3 | 25 | 1 | US | May 18, 2016 | Apr 14, 2014 |
| Durvalumab | Approved | Phase 3 | 12 | 4 | 1 | 25 | 2 | US | May 1, 2017 | Dec 28, 2016 |
| Nadofaragene Firadenovec | Approved | Phase 4 | 1 | 0 | 1 | 4 | 1 | EU | May 28, 2026 | 2012-09 |
| Nogapendekin Alfa Inbakicept | Approved | Phase 1 | 1 | 0 | 0 | 1 | 2 | EU, US | Apr 22, 2024 | 2026-12 |
| Thiotepa | Approved | — | 0 | 0 | 0 | 0 | 1 | US | Jan 26, 2017 | — |
| Epirubicin | Phase 4 | Phase 4 | 3 | 1 | 2 | 5 | 0 | — | — | 2009-10 |
| Metformin | Phase 4 | Phase 4 | 1 | 1 | 0 | 3 | 0 | — | — | 2015-10 |
| Nivolumab | Phase 3 | Phase 3 | 15 | 3 | 3 | 30 | 0 | — | — | Jul 22, 2015 |
| Docetaxel | Phase 3 | Phase 3 | 10 | 3 | 5 | 27 | 0 | — | — | 1997-08 |
| Fluorouracil | Phase 3 | Phase 3 | 9 | 2 | 4 | 16 | 0 | — | — | 1997-12 |
| Carboplatin | Phase 3 | Phase 3 | 8 | 3 | 5 | 32 | 0 | — | — | 1997-12 |
| Cabozantinib | Phase 3 | Phase 3 | 6 | 2 | 1 | 8 | 0 | — | — | Jul 22, 2015 |
| Paclitaxel | Phase 3 | Phase 3 | 5 | 1 | 7 | 38 | 0 | — | — | 1995-05 |
| Avelumab | Phase 3 | Phase 3 | 5 | 0 | 2 | 14 | 0 | — | — | Feb 23, 2018 |
| Sacituzumab Govitecan | Phase 3 | Phase 3 | 4 | 3 | 1 | 6 | 0 | — | — | Jun 1, 2019 |
| Toripalimab | Phase 3 | Phase 3 | 4 | 1 | 1 | 6 | 0 | — | — | Jan 4, 2021 |
| Disitamab Vedotin | Phase 3 | Phase 3 | 4 | 2 | 1 | 4 | 0 | — | — | Apr 1, 2024 |
| Bacillus Calmette-Guerin BCG | Phase 3 | Phase 3 | 3 | 0 | 1 | 6 | 0 | — | — | 2009-09 |
| Eribulin | Phase 3 | Phase 3 | 3 | 0 | 1 | 4 | 0 | — | — | Oct 23, 2006 |
| Methotrexate | Phase 3 | Phase 3 | 2 | 0 | 5 | 18 | 0 | — | — | 1996-11 |
| Vinblastine | Phase 3 | Phase 3 | 2 | 0 | 5 | 17 | 0 | — | — | 1996-11 |
| Pemetrexed | Phase 3 | Phase 3 | 2 | 1 | 1 | 5 | 0 | — | — | Aug 10, 2004 |
| Datopotamab Deruxtecan | Phase 3 | Phase 3 | 2 | 1 | 1 | 2 | 0 | — | — | Nov 12, 2020 |
| Doxorubicin | Phase 3 | Phase 3 | 1 | 0 | 6 | 22 | 0 | — | — | 1996-11 |
| Vinflunine | Phase 3 | Phase 3 | 1 | 1 | 4 | 8 | 0 | — | — | 2005-01 |
| Bevacizumab | Phase 3 | Phase 3 | 1 | 0 | 1 | 5 | 0 | — | — | Sep 21, 2005 |
| Capecitabine | Phase 3 | Phase 3 | 1 | 0 | 1 | 1 | 0 | — | — | Oct 20, 2026 |
| Filgrastim | Phase 3 | Phase 3 | 0 | 0 | 3 | 14 | 0 | — | — | 1996-11 |
| Lapatinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 5 | 0 | — | — | 2006-02 |
| Gefitinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 4 | 0 | — | — | 2001-02 |
| Sirolimus | Phase 3 | Phase 3 | 0 | 0 | 1 | 4 | 0 | — | — | 2012-03 |
| Valrubicin | Phase 3 | Phase 3 | 0 | 0 | 2 | 4 | 0 | — | — | 1993-11 |
| Celecoxib | Phase 3 | Phase 3 | 0 | 0 | 1 | 3 | 0 | — | — | 2000-06 |
| Dexamethasone | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2004-02 |
| Ipilimumab | Phase 2 | Phase 2 | 5 | 1 | 0 | 5 | 0 | — | — | Jul 22, 2015 |
| Cyclophosphamide | Phase 2 | Phase 2 | 4 | 2 | 0 | 7 | 0 | — | — | Jul 3, 2014 |
| Erdafitinib | Phase 2 | Phase 2 | 4 | 0 | 0 | 5 | 0 | — | — | Aug 17, 2015 |
| Tremelimumab | Phase 2 | Phase 2 | 3 | 0 | 0 | 9 | 0 | — | — | Dec 28, 2016 |
| Etoposide | Phase 2 | Phase 2 | 3 | 2 | 0 | 4 | 0 | — | — | 1998-07 |
| Leucovorin | Phase 2 | Phase 2 | 3 | 0 | 0 | 3 | 0 | — | — | Apr 23, 2003 |
| Chemotherapy | Phase 2 | Phase 2 | 2 | 0 | 0 | 6 | 0 | — | — | 2000-03 |
| Cemiplimab | Phase 2 | Phase 2 | 2 | 2 | 0 | 5 | 0 | — | — | Feb 11, 2022 |
| Fludarabine | Phase 2 | Phase 2 | 2 | 1 | 0 | 5 | 0 | — | — | Jul 3, 2014 |
| Tislelizumab | Phase 2 | Phase 2 | 2 | 0 | 0 | 5 | 0 | — | — | Dec 1, 2020 |
| Sapanisertib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.